Data manager wanted
DeWorm3 is currently seeking a data manager with experience of harmonising the collection, cleaning, sharing and storage of data across multiple trial sites.
The position provides a unique opportunity to be a part of a series of rigorous, community-based randomised controlled trials that aim to inform future global health policies on the elimination of soil-transmitted helminthiasis.
How to apply
Find full details about this role and submit your application on the Museum's recruitment website.
Having received a large number of proposals of a high standard we are very pleased to announce that the selection of the main DeWorm3 trail site is now complete.
Following the final recommendations provided by the external review panel, the following research partners for the main DeWorm3 trial sites were identified:
- Benin - Institut de Recherche Clinique du Bénin (IRCB); Institut de Recherche pour le Développement (IRD).
- India - Christian Medical College (CMC) Vellore; Imperial College London.
- Malawi - Blantyre Institute for Community Ophtalmology (BICO); London School of Hygiene and Tropical Medicine.
In addition, some other sites may be considered for sub-studies, given any available funding.
All eligible applications were reviewed by an independent, external panel of experts with experience in leading large trials and reviewing applications for large funding agencies.
The panel was comprised of the following members:
Chair: Professor Jimmy Whitworth (London School of Hygiene and Tropical Medicine)
- Professor Dan Colley (University of Georgia)
- Professor John Gyapong (University of Ghana)
- Dr. Harriet Mpairwe (Medical Research Council Uganda/Uganda Virus Research Institute)
- Professor Ric Price (Menzies School of Health Research/ University of Oxford)
(Please note: these individuals should not be contacted directly regarding the review process; all communication should go through Dr Judd Walson.)
The following six applications were selected for site visits:
Benin - Institut de Recherche Clinique du Bénin (IRCB); Institut de Recherche pour le Développement (IRD).
Cameroon - Centre for Schistosomiasis and Parasitology (CSP); National Programme for the Control of Schistosomiasis and Intestinal Helminthiasis, Ministry of Health.
India - Christian Medical College (CMC) Vellore; Imperial College London.
Ivory Coast - Centre Suisse de Recherches Scientifiques en Côte d’Ivoire (CSRS); Swiss Tropical and Public Health Institute (Swiss TPH).
Malawi - Blantyre Institute for Community Ophtalmology (BICO); London School of Hygiene and Tropical Medicine.
Sri Lanka - Faculty of Medicine, University of Kelaniya.
The site visits took place in May and June were an opportunity for the DeWorm3 team to meet with the shortlisted group of applicants and their partners to assess the applicants’ abilities to conduct large field trials.
A comprehensive analysis of strengths, weaknesses, opportunities and threats (SWOT) was conducted through a consistent, systematic and objective assessment of the epidemiological setting, partnerships, institutional, laboratory and data management capacities as outlined in the request for proposals.
If you have any further questions please contact the DeWorm3 team.
We will test the feasibility of eliminating soil-transmitted helminths (STHs, or intestinal worms) and developing cost-effective methods for scaling up elimination programs.
Over 1.45 billion people are infected with soil-transmitted helminths (STHs), including 845 million children, in some of the world’s poorest communities.
The project will be led by a team at the Natural History Museum in London and will last for five-years, in the first instance. Museum scientists have a long history of researching disease and understanding the identity, nature and diversification of parasites and vectors.
The DeWorm3 project aims to
- demonstrate the feasibility of eliminating STHs using existing and intensified mass drug administration (MDA) strategies, specifically by leveraging existing lymphatic filariasis elimination platforms
- inform the guidelines, policies, and operational plans needed to successfully achieve STH elimination
- link qualitative and operational studies of the acceptability and feasibility of different strategies to ongoing field trials, guiding future implementation and scale-up plans.
STHs reduce the body’s ability to absorb nutrients and vitamins. This can exacerbat malnutrition and lead to anaemia, increased susceptibility to other infectious diseases, stunted growth and impaired cognitive development.
STHs are a group of intestinal parasites that thrive in areas with warm, humid soil and poor sanitation. The most common STH parasites are nematodes, including roundworm (Ascaris), whipworm (Trichuris), and hookworm (Ancylostoma and Necator).
STHs are controlled primarily through school-based mass drug administration (MDA) programmes where albendazole or mebendazole are given to children.
However, recent studies suggest that successfully interrupting the transmission of STHs may require broadening treatment to pre-school-age children and adults through community-based MDA platforms.
In addition, alternative combinations or delivery schedules of antihelminthic drugs may be required to break transmission of these diseases.
STHs share a co-indicated drug (albendazole) and are geographically congruent with other neglected tropical diseases (NTDs), including lymphatic filariasis. This creates the potential for a coordinated elimination approach.
However, strategies to inform guidelines in countries transitioning from disease control to elimination in an integrated fashion have not been fully evaluated.
- Conduct field trials to assess optimal strategies for interrupting disease transmission and reducing morbidity.
- Develop implementation strategies to achieve successful STHs elimination at scale.
- Develop clear definitions (epidemiologic and operational) of STHs transmission interruption.